Rivopharm
Rivopharm SA, founded in 1961 and headquartered in Manno, Switzerland, develops, manufactures, and distributes generic pharmaceutical products across psychiatric, antidiabetic, antiepileptic, and cardiovascular therapeutic areas to patients, physicians, and pharmacists in over 60 countries, operating under Swissmedic-approved facilities and via subsidiaries in the UK, Germany, and Lithuania.
- Company typePrivate
- Founded1961
- HeadquartersManno, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rivopharm does
Rivopharm SA is a Swiss specialty pharmaceutical company founded in 1961 and headquartered in Manno, Canton Ticino. The company develops, manufactures, and commercializes generic pharmaceutical products, primarily in oral dosage form, across therapeutic areas that include psychiatric, antidepressant, anti-inflammatory, antiepileptic, antidiabetic, and coronary vasodilator treatments. Representative products include Repaglinide 0.5mg 90 (generic of NovoNorm, for diabetes), Nicorandil 10mg 30 (generic of Dancor, for angina), and Levetiracetam 500mg 200 (generic of Keppra, for epilepsy). The Manno facility is operated by over 200 staff and is inspected and approved by Swissmedic, the Swiss authority responsible for drug and medical device authorization. Underpinning operations is a branded framework called "Swiss Pharma Solutions," which integrates quality assurance, regulatory compliance, and reliability into a full-cycle offering from pre-formulation through validation, packaging, and final distribution. Customers are reached through direct engagement with physicians and pharmacists; the company cites 360-degree management from production to distribution across more than 60 countries. Pricing is not publicly disclosed, and generics are positioned as affordable alternatives to originator medications — patients reportedly pay approximately 10% of drug cost compared with roughly 20% for original medications.
The company operates through a group structure comprising wholly-owned subsidiaries: Developharma SA (Manno, an R&D arm offering pre-formulation through final registration services to Rivopharm and third-party companies), Rivopharm UK Ltd (London, distribution and commercialization), Holsten Pharma GMBH (Frankfurt, distribution and commercialization), and Sanoswiss UAB (Vilnius, medical information and pharmacovigilance). This multi-jurisdiction European footprint supports regulatory-aware commercialization and adverse-event monitoring across key European markets. Strategic partners include Laprophan Group (Morocco), which acquired a controlling stake in June 2026 via its Luxembourg platform Europhan, representing Laprophan's first European acquisition and positioning the combined entity as a diversified international pharmaceutical platform spanning Europe, Africa, and the Middle East. The deal added approximately US$100 million in annual revenue to Laprophan; financial terms of the acquisition were not disclosed, and integration efforts are underway.
Following the Laprophan transaction, Rivopharm continues to operate independently at the operational level, with its website and Manno-based manufacturing remaining active. Headcount is reported at 200+ at the Swiss site, with a small but distributed European commercial and pharmacovigilance network. The company has no disclosed patents, trademarks, awards, or funding rounds; revenue mechanics rely on generic product sales through wholesale and pharmacy channels rather than licensing or platform-based models.
Rivopharm firmographics
Firmographics- Name
- Rivopharm
- Legal name
- Rivopharm SA
- Website
- https://rivopharm.ch
- Company type
- Private
- Founded year
- 1961
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Rivopharm SA, founded in 1961 and headquartered in Manno, Switzerland, develops, manufactures, and distributes generic pharmaceutical products across psychiatric, antidiabetic, antiepileptic, and cardiovascular therapeutic areas to patients, physicians, and pharmacists in over 60 countries, operating under Swissmedic-approved facilities and via subsidiaries in the UK, Germany, and Lithuania.
- Ownership category
- akta.pro rank
Rivopharm industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Rivopharm is headquartered
LocationHeadquarters
- HQ city
- Manno
- HQ country
- Switzerland
- HQ region
- Europe
Offices5 records
Markets served
Rivopharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Products: Rivopharm generates revenue through the development, production, and commercialization of generic pharmaceutical products. The company adds approximately US$100 million in annual revenue, based on Laprophan's acquisition announcement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Rivopharm product offering
Product offeringCore offering
Rivopharm develops, produces, and commercializes generic pharmaceutical products globally, with a primary focus on standard oral dosage generic forms. The therapeutic portfolio covers psychiatric, antidepressant, anti-inflammatory, antiepileptic, antidiabetic, and coronary vasodilator medications, distributed in more than 60 countries. Through subsidiary Developharma SA, the company also provides specialized pharmaceutical R&D services from pre-formulation through final registration, both for its own products and for third-party companies.
Product overview
Rivopharm is a Swiss pharmaceutical company that develops, produces, and commercializes generic pharmaceutical products globally. The company's product portfolio includes generic medications across therapeutic areas including antidiabetics (Repaglinide), coronary vasodilators (Nicorandil), and antiepileptics (Levetiracetam). Products are organized by category: Antidiabetics, Antiepileptics, and Vasodilatators. The company operates through its R&D subsidiary Developharma SA and distributes to more than 60 countries worldwide. The group was founded in 1961 and is headquartered in Manno, Canton Ticino, Switzerland.
Differentiator
Problem solved
Functional benefit
Products and services
- Repaglinide 0.5mg 90
Quantifiable outcome
- Patients save over 100 CHF per year on average by using generic medications
- +1 more outcomes
Companies that use Rivopharm
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Rivopharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Rivopharm partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Sanoswiss UABcoreSanoswiss UAB manages medical information and drug safety services on behalf of Rivopharm. Located in Vilnius, Lithuania, they handle adverse reaction reports and medical information requests. Contact: [email protected], +370 700 15 140
- Developharma SAcoreR&D focused structure providing highly specialized support and services in the pharmaceutical field both directly to Rivopharm and to third-party companies, either exclusively or for joint venture projects. All activities from pre-formulation to final registration are conducted in compliance with good laboratory and sector practices, inspected and approved by Swissmedic.
- Volley LuganominorMain sponsor since 2015 of Volley Lugano, a sports club always attentive to youth sector development.
- Hockey Club LuganominorPartner since 2020 of Hockey Club Lugano, winner of 7 national titles.
- Laprophan GroupcoreMorocco's leading pharmaceutical company acquired a controlling stake in Rivopharm through its Luxembourg-based European platform Europhan. This represents Laprophan's first acquisition in Europe, positioning them to build a diversified international pharmaceutical platform spanning Europe, Africa, and the Middle East.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
Rivopharm competitors and assessment
Company assessmentBroad incumbents
- Sandoz: Sandoz is the world's largest generics manufacturer, headquartered in Basel, Switzerland. As a Swiss-headquartered specialty generic producer distributing globally, it is the most directly comparable scale player to Rivopharm.
- Teva Pharmaceutical Industries: Teva is the world's largest generic drugmaker with an extensive specialty and generics portfolio. It represents a major competitive incumbent for Rivopharm's therapeutic categories.
- Viatris: Viatris is a global generics and specialty pharmaceutical company formed from Mylan and Upjohn. It competes with Rivopharm across European and emerging-market generic distribution channels.
Direct peers
- Stada Arzneimittel: Stada is a European-focused specialty generics and consumer healthcare company headquartered in Germany. It serves similar European pharmacy channels with a comparable portfolio of niche and specialty generic molecules.
- KRKA: KRKA is a Slovenian specialty generic manufacturer with global distribution and a portfolio emphasis on niche therapeutic areas. It is closely comparable to Rivopharm in scale, geographic reach, and focus on differentiated oral solid generics.
- Polpharma Group: Polpharma is a Central European generics manufacturer serving European and CIS markets with a portfolio of generic prescription medicines. Comparable to Rivopharm as a mid-size regional generics specialist.
- Glenmark Pharmaceuticals: Glenmark is an India-headquartered specialty generics manufacturer with global distribution including Europe and emerging markets. Comparable to Rivopharm in therapeutic-area focus and geographic breadth.
Emerging players
- Alvotech: Alvotech is an Iceland-based specialty generics and biosimilars company with operations across Europe and emerging markets. Comparable to Rivopharm as a smaller-scale, regulatory-quality-focused generics platform.
Regional players
- Mepha Pharma (Helvepharm): Mepha is a Swiss generics manufacturer serving primarily the Swiss domestic market. Comparable to Rivopharm as a Swiss-headquartered generic company with similar therapeutic focus, though narrower in geographic scope.
Others
- Laprophan Group: Laprophan is Morocco's leading pharmaceutical company and Rivopharm's new controlling shareholder via Europhan. As parent, it is an adjacent/strategic peer in generic pharma distribution across Africa and the Middle East.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Rivopharm social profiles
Digital presenceRivopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rivopharm leadership team
Management profileNumber of profiles
Rivopharm subsidiaries and ownership
Company hierarchySubsidiaries4 records
Rivopharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rivopharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rivopharm
What does Rivopharm do?
Rivopharm develops, produces, and commercializes generic pharmaceutical products globally, with a primary focus on standard oral dosage generic forms. The therapeutic portfolio covers psychiatric, antidepressant, anti-inflammatory, antiepileptic, antidiabetic, and coronary vasodilator medications, distributed in more than 60 countries. Through subsidiary Developharma SA, the company also provides specialized pharmaceutical R&D services from pre-formulation through final registration, both for its own products and for third-party companies.
Is Rivopharm a public or private company?
Rivopharm is a private company. It is classified as corporate owned and is currently operating.
When was Rivopharm founded?
Rivopharm was founded in 1961. It employs 101 to 250 people.
Where is Rivopharm based?
Rivopharm is headquartered in Manno, Switzerland, in the Europe region.
How does Rivopharm make money?
One revenue line is on record: generic Pharmaceutical Products.
Who are Rivopharm's main competitors?
Broad incumbents on record are Sandoz, Teva Pharmaceutical Industries and Viatris. Direct peers are Stada Arzneimittel, KRKA, Polpharma Group and Glenmark Pharmaceuticals. Alvotech is listed as an emerging player. Mepha Pharma (Helvepharm) is listed as a regional player. Laprophan Group is listed as an others.
Does Rivopharm have an API?
No public API is recorded for Rivopharm.
What industry is Rivopharm in?
Rivopharm's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.